Cell and Gene Therapy Manufacturing Market: Automation, AI Integration, and Global Partnerships Accelerate Industry Expansion Through 2034

Subheadline:
Rising investment in regenerative medicine, advanced manufacturing platforms, and automated bioprocessing systems are transforming the global cell and gene therapy manufacturing landscape.

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72379

Introduction
The Cell and Gene Therapy Manufacturing Market is at the forefront of the biotechnology revolution, driven by unprecedented demand for personalized medicine, automation in bioprocessing, and expanding clinical pipelines.
Valued at USD 14.3 billion in 2024, the market is projected to reach USD 38.5 billion by 2034, growing at an impressive CAGR of 10.2%.

The rapid approval of novel therapies targeting rare genetic disorders, cancers, and autoimmune diseases is redefining how medicines are developed, produced, and delivered. Meanwhile, advanced manufacturing technologies are helping companies overcome scalability and cost challenges, bringing next-generation therapies closer to patients.

Key Players in the Market
The competitive landscape features global biopharma leaders, contract development and manufacturing organizations (CDMOs), and technology providers.

Major players include:
• Lonza Group AG
• Thermo Fisher Scientific Inc.
• Catalent Inc.
• Samsung Biologics
• Oxford Biomedica plc
• WuXi Advanced Therapies Inc.
• Fujifilm Diosynth Biotechnologies
• Novartis AG
• Bluebird Bio, Inc.
• Sartorius AG

These players are expanding capabilities in viral vector manufacturing, closed-system automation, and AI-based process analytics, enabling faster, more consistent production of cell and gene therapies (CGTs).

Key Events in the Last Five Years
• 2020-2021: The COVID-19 pandemic accelerated investment in biomanufacturing infrastructure, benefitting advanced therapy developers.
• 2022: Thermo Fisher and Catalent launched modular facilities for viral vector and plasmid DNA production.
• 2023: Lonza partnered with Vertex Pharmaceuticals to expand manufacturing for gene-edited cell therapies.
• 2024: AI-driven bioprocess modeling became central to optimizing yield and reducing variability across CGT production lines.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/72379/joint-pain-injections-market

Market Growth Rate
According to Exactitude Consultancy, the cell and gene therapy manufacturing industry will expand at a CAGR of 10.2% (2025-2034), supported by:
• Rising clinical and commercial approvals for CGTs across oncology, neurology, and rare diseases.
• Automation and digital transformation in bioprocessing systems.
• Expanding global CDMO networks catering to both startups and large biopharma clients.
• Government and venture capital investments accelerating manufacturing capacity and quality compliance.

Market Segments and Growth Analysis

The market is segmented by therapy type, mode of manufacturing, scale, and region.
By Therapy Type:
• Cell Therapy (CAR-T, TCR-T, Stem Cell-Based)
• Gene Therapy (Viral Vector-Based, Non-Viral Delivery)
• Tissue-Engineered Products

By Mode of Manufacturing:
• In-House Manufacturing
• Contract Manufacturing (CDMOs)

By Scale:
• Clinical-Scale Manufacturing
• Commercial-Scale Manufacturing

By Region:
• North America: Leads with strong FDA regulatory support and advanced CGT infrastructure.
• Europe: Expanding due to favorable EMA guidelines and innovation hubs in the UK, Germany, and Switzerland.
• Asia Pacific: Fastest-growing region, led by Japan, South Korea, and China's biotech clusters.
• Latin America & MEA: Emerging facilities and technology partnerships improving access to CGT research platforms.

Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72379

Key Market Drivers
1. Surge in Cell and Gene Therapy Approvals:
Over 2,000 ongoing clinical trials worldwide are accelerating manufacturing demand.
2. Adoption of Automation and AI:
Digital twins, machine learning, and closed-system automation are improving batch consistency and reducing contamination risk.
3. Expanding CDMO Capacity:
Outsourcing manufacturing remains a key trend for startups seeking scalable, GMP-compliant production.
4. Government Incentives and Funding:
Initiatives like the U.S. ARPA-H and EU Horizon Europe programs are boosting capacity for advanced therapy production.

Recent Developments
• 2023: Samsung Biologics announced a USD 1.5 billion investment to expand its gene therapy CDMO capabilities in South Korea.
• 2024: Fujifilm Diosynth partnered with Bluebird Bio to scale viral vector production for lentiviral platforms.
• 2024: Lonza launched an AI-enabled Cocoon Platform for decentralized cell therapy manufacturing.
• 2024: Sartorius AG introduced single-use bioreactors designed specifically for autologous cell therapy workflows.

Expert Insight
"The manufacturing of cell and gene therapies is no longer experimental-it's entering industrial scale. Automation, modular facilities, and AI are the key enablers of cost-effective and globally accessible CGT manufacturing,"
- Dr. Emily Howard, Head of Bioprocess Innovation, MIT Center for Biomedical Engineering.

Conclusion
The Cell and Gene Therapy Manufacturing Market represents the next frontier in biopharmaceutical production, combining precision engineering with medical innovation.

As digital bioprocessing, AI integration, and global collaboration expand, manufacturing bottlenecks are being replaced by scalable, efficient platforms.
By 2034, CGT manufacturing will become a cornerstone of personalized healthcare, driving unprecedented opportunities for both patients and industry stakeholders.

This report is also available in the following languages : Japanese (関節痛注射市場), Korean (관절 통증 주사 시장), Chinese (关节疼痛注射市场), French (Marché des injections contre les douleurs articulaires), German (Markt für Injektionen gegen Gelenkschmerzen), and Italian (Mercato delle iniezioni per il dolore articolare), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72379

Our More Reports:

Scleritis Market
https://exactitudeconsultancy.com/reports/72281/scleritis-market

Persistent Epithelial Defect Market
https://exactitudeconsultancy.com/reports/72290/persistent-epithelial-defect-market

Uveitis Patient Pool Analysis, Market
https://exactitudeconsultancy.com/reports/72310/uveitis-patient-pool-analysis-market

Cell and Gene Therapy Manufacturing Market
https://exactitudeconsultancy.com/reports/72365/cell-and-gene-therapy-manufacturing-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.